person · Reporting owner
Kurzius Lawrence Erik
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COOPER COMPANIES, INC.COO · Entity 3395 | Director | September 16, 2026 | September 17, 2026 |
| Elanco Animal Health IncELAN · Entity 3457 | Director | August 20, 2026 | August 21, 2026 |
| Lamb Weston Holdings, Inc.LW · Entity 3684 | Director | October 08, 2026 | October 09, 2026 |
| MCCORMICK & CO INCMKC · Entity 1416 | 10% owner | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COOPER COMPANIES, INC.
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,099 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Purchase · Acquired 10,000 · Balance 31,099 |
Elanco Animal Health Inc
Report date August 20, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 188,647 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Purchase · Acquired 40,000 · Balance 188,647 F1: Reflects the weighted average price of 40,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on August 20, 2026 with purchase prices ranging from $23.385 to $23.40 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the weighted average price of 40,000 shares of common stock of Elanco Animal Health Inc. purchased by the reporting person in multiple transactions on August 20, 2026 with purchase prices ranging from $23.385 to $23.40 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Lamb Weston Holdings, Inc.
Report date October 08, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,054 |
Reported balance
After 2026-10-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-08 · Grant · Acquired 5,458 · Balance 11,054 F1: Represents restricted stock units ("RSUs") that vest on the earlier of (1) the first anniversary of the date of grant and (2) the date of the next annual meeting of Lamb Weston Holdings, Inc.'s ("Lamb Weston") stockholders that is at least 50 weeks after September 16, 2026, or earlier upon certain events. Each RSU represents a contingent right to receive one share of Lamb Weston common stock upon settlement. F2: Includes 135 additional shares acquired since the date of the reporting person's last report through a dividend reinvestment feature. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that vest on the earlier of (1) the first anniversary of the date of grant and (2) the date of the next annual meeting of Lamb Weston Holdings, Inc.'s ("Lamb Weston") stockholders that is at least 50 weeks after September 16, 2026, or earlier upon certain events. Each RSU represents a contingent right to receive one share of Lamb Weston common stock upon settlement.
F2: Includes 135 additional shares acquired since the date of the reporting person's last report through a dividend reinvestment feature.
MCCORMICK & CO INC
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock - VotingSEC Table I · non-derivative | Direct | 296,992 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 205,538 · Balance 502,530 Row 2 · 2026-08-10 · Sale · Disposed 205,538 · Balance 296,992 |
| Options - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $49.03 · Expires 2027-03-29 | Direct | 0 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 205,538 · Balance 0 F1: Option exercised; no purchase price required. |
Filing footnotes · ownership attribution and instrument terms
F1: Option exercised; no purchase price required.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2021 Filed Feb 1, 2022 19:14 UTC | MCCORMICK & CO INC MKC · Entity 1416 | OtherPhantom Stock · Derivative | 123.697 | $81.06 | $10,026.88 |
DisclosureSEC source: 0001062993-22-001948 · form4.xml · derivative · entry 14 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Retirement Plan Disclosed balance after: 29,315.417 Underlying: Common Stock - Voting · 123.697 shares Expires not disclosed F2 · derivative.exercise_price: Dividend Reinvestment. F2 · derivative.exercise_date: Dividend Reinvestment. F2 · derivative.expiration_date: Dividend Reinvestment. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:19 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 224.731 | $31.89 | $7,166.67 |
DisclosureSEC source: 0001179110-21-009148 · edgar.xml · derivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,158.3769 Underlying: Common Stock · 224.731 shares Expires not disclosed F1 · security: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $31.89 on September 30, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $31.89 on September 30, 2021. F1 · derivative.exercise_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 20:26 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 214.6995 | $33.38 | $7,166.67 |
DisclosureSEC source: 0001235110-21-000030 · edgar.xml · derivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,933.6459 Underlying: Common Stock · 214.6995 shares Expires not disclosed F1 · security: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $33.38 on August 31, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $33.38 on August 31, 2021. F1 · derivative.exercise_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 20:52 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 196.5086 | $36.37 | $7,147.02 |
DisclosureSEC source: 0000950138-21-000406 · edgar.xml · derivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,718.9464 Underlying: Common Stock · 196.5086 shares Expires not disclosed F1 · security: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $36.37 on July 30, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $36.37 on July 30, 2021. F1 · derivative.exercise_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| July 26, 2021 Filed Feb 1, 2022 19:14 UTC | MCCORMICK & CO INC MKC · Entity 1416 | OtherPhantom Stock · Derivative | 116.973 | $85.38 | $9,987.15 |
DisclosureSEC source: 0001062993-22-001948 · form4.xml · derivative · entry 13 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Retirement Savings Plan Disclosed balance after: 29,191.72 Underlying: Common Stock - Voting · 116.973 shares Expires not disclosed F2 · derivative.exercise_price: Dividend Reinvestment. F2 · derivative.exercise_date: Dividend Reinvestment. F2 · derivative.expiration_date: Dividend Reinvestment. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:56 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 206.5918 | $34.69 | $7,166.67 |
DisclosureSEC source: 0000950138-21-000374 · edgar.xml · derivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,522.4378 Underlying: Common Stock · 206.5918 shares Expires not disclosed F1 · security: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $34.69 on June 30, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $34.69 on June 30, 2021. F1 · derivative.exercise_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:41 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 199.1848 | $35.98 | $7,166.67 |
DisclosureSEC source: 0000950138-21-000313 · edgar.xml · derivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,315.846 Underlying: Common Stock · 199.1848 shares Expires not disclosed F1 · security: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $35.98 on May 28, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $35.98 on May 28, 2021. F1 · derivative.exercise_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| April 30, 2021 Filed May 4, 2021 00:00 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 226.0066 | $31.71 | $7,166.67 |
DisclosureSEC source: 0000950138-21-000292 · edgar.xml · derivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,116.6612 Underlying: Common Stock · 226.0066 shares Expires not disclosed F1 · security: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $31.71 on April 30, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $31.71 on April 30, 2021. F1 · derivative.exercise_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| April 26, 2021 Filed Apr 30, 2021 14:51 UTC | MCCORMICK & CO INC MKC · Entity 1416 | OtherPhantom Stock · Derivative | 110.1232 | $90.35 | $9,949.63 |
DisclosureSEC source: 0000063754-21-000100 · edgar.xml · derivative · entry 8 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Retirement Savings Plan Disclosed balance after: 29,074.747 Underlying: Common Stock - Voting · 110.1232 shares Expires not disclosed F1 · derivative.exercise_price: Dividend Reinvestment. F1 · derivative.exercise_date: Dividend Reinvestment. F1 · derivative.expiration_date: Dividend Reinvestment. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 13:58 UTC | MCCORMICK & CO INC MKC · Entity 1416 | GiftCommon Stock - Voting | 110,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000063754-21-000092 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,849 F1 · price: Shares gifted; no purchace price required. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 13:16 UTC | MCCORMICK & CO INC MKC · Entity 1416 | GrantOptions - Right to Buy · Derivative | 220,589 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0000063754-21-000076 · edgar.xml · derivative · entry 9 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,589 Underlying: Common Stock - Voting · 220,589 shares Expires not disclosed F2 · derivative.exercise_date: The option grant becomes exercisable in thirds of each of the first three (3) grant anniversaries. F2 · derivative.expiration_date: The option grant becomes exercisable in thirds of each of the first three (3) grant anniversaries. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 22:08 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 243.3504 | $29.45 | $7,166.67 |
DisclosureSEC source: 0000950138-21-000248 · edgar.xml · derivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,890.6546 Underlying: Common Stock · 243.3504 shares Expires not disclosed F1 · security: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $29.45 on March 31, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $29.45 on March 31, 2021. F1 · derivative.exercise_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 21:24 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionRestricted Stock Units · Derivative | 7,966 | $0.00 | $0.00 |
DisclosureSEC source: 0000063754-21-000058 · edgar.xml · derivative · entry 16 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,936 Underlying: Common Stock - Voting · 7,966 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; No purchase price required. F9 · price: Restricted Stock Units granted on April 1, 2020. F8 · derivative.exercise_date: The Restricted Stock Units vest in thirds over a three year period beginning March 15, 2021, March 15, 2022 and March 15, 2023. F8 · derivative.expiration_date: The Restricted Stock Units vest in thirds over a three year period beginning March 15, 2021, March 15, 2022 and March 15, 2023. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 21:24 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionRestricted Stock Units · Derivative | 6,994 | $0.00 | $0.00 |
DisclosureSEC source: 0000063754-21-000058 · edgar.xml · derivative · entry 15 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,994 Underlying: Common Stock - Voting · 6,994 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; No purchase price required. F7 · price: Restricted Stock Units granted on March 27, 2019 F6 · derivative.exercise_date: The Restricted Stock Units vest in thirds over a three year period beginning March 15, 2020, March 15, 2021 and March 15, 2022 F6 · derivative.expiration_date: The Restricted Stock Units vest in thirds over a three year period beginning March 15, 2020, March 15, 2021 and March 15, 2022 Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 21:24 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionRestricted Stock Units · Derivative | 8,502 | $0.00 | $0.00 |
DisclosureSEC source: 0000063754-21-000058 · edgar.xml · derivative · entry 14 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 8,502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; No purchase price required. F5 · price: Restricted Stock Units granted on March 28, 2018. F4 · derivative.exercise_date: The Restricted Stock Units vest in thirds over a three year period beginning March 15, 2019, March 15, 2020 and March 15, 2021. F4 · derivative.expiration_date: The Restricted Stock Units vest in thirds over a three year period beginning March 15, 2019, March 15, 2020 and March 15, 2021. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 21:24 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Tax withholdingCommon Stock - Voting | 3,661 | $86.18 | $315,486.68 |
DisclosureSEC source: 0000063754-21-000058 · edgar.xml · nonDerivative · entry 6 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,849 F2 · balance_after: The Reporting Person's direct holdings of the Issuer's Common Stock - Voting decreased by 29,096 shares as a result of such shares being transferred on February 26, 2021 and evenly split into two seperate grantor retained annuity trusts of which the Reporting Person is a trustee and sole annuitant. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 21:24 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionCommon Stock - Voting | 7,966 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000063754-21-000058 · edgar.xml · nonDerivative · entry 5 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; No purchase price required. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 21:24 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Tax withholdingCommon Stock - Voting | 3,214 | $86.18 | $276,966.45 |
DisclosureSEC source: 0000063754-21-000058 · edgar.xml · nonDerivative · entry 4 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,640 Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 21:24 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionCommon Stock - Voting | 6,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000063754-21-000058 · edgar.xml · nonDerivative · entry 3 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; No purchase price required. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 21:24 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Tax withholdingCommon Stock - Voting | 3,907 | $86.18 | $336,685.73 |
DisclosureSEC source: 0000063754-21-000058 · edgar.xml · nonDerivative · entry 2 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,860 Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 21:24 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionCommon Stock - Voting | 8,502 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000063754-21-000058 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; No purchase price required. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 22:05 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 218.0971 | $32.86 | $7,166.67 |
DisclosureSEC source: 0000950138-21-000164 · edgar.xml · derivative · entry 2 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,647.3042 Underlying: Common Stock · 218.0971 shares Expires not disclosed F1 · security: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F4 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $32.86 on February 26, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F4 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $32.86 on February 26, 2021. F1 · derivative.exercise_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 16:17 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Tax withholdingCommon Stock - Voting | 18,080 | $89.80 | $1,623,493.60 |
DisclosureSEC source: 0000063754-21-000034 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,748 F1 · shares: Shares withheld for taxes on the shares previously reported on 1/26/2021 for McCormick's Long-Term Incentive Plan. Read SEC document |
| January 29, 2021 Filed Mar 2, 2021 22:05 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 246.8712 | $29.03 | $7,166.67 |
DisclosureSEC source: 0000950138-21-000164 · edgar.xml · derivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,429.2071 Underlying: Common Stock · 246.8712 shares Expires not disclosed F1 · security: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $29.03 on January 29, 2021. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $29.03 on January 29, 2021. F1 · derivative.exercise_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 19:28 UTC | MCCORMICK & CO INC MKC · Entity 1416 | GrantCommon Stock - Voting | 37,432 | $0.00 | $0.00 |
DisclosureSEC source: 0000063754-21-000010 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,828 F1 · shares: Shares awarded pursuant to McCormick's Long-Term Incentive Program (LTIP) for the three (3) year performance cycle beginning on December 1, 2017 and ending on November 30, 2020 Read SEC document |
| January 11, 2021 Filed Jan 26, 2021 19:28 UTC | MCCORMICK & CO INC MKC · Entity 1416 | OtherPhantom Stock · Derivative | 105.8811 | $93.63 | $9,913.65 |
DisclosureSEC source: 0000063754-21-000010 · edgar.xml · derivative · entry 6 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Retirement Savings Plan Disclosed balance after: 28,964.6241 Underlying: Common Stock - Voting · 105.8811 shares Expires not disclosed F2 · derivative.exercise_price: Dividend Reinvestment. F2 · derivative.exercise_date: Dividend Reinvestment. F2 · derivative.expiration_date: Dividend Reinvestment. Read SEC document |
| December 31, 2020 Filed Feb 16, 2021 21:31 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantDeferred Stock Units · Derivative | 233.6704 | $30.67 | $7,166.67 |
DisclosureSEC source: 0000950138-21-000125 · edgar.xml · derivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,182.3359 Underlying: Common Stock · 233.6704 shares Expires not disclosed F1 · security: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $30.67 on December 31, 2020. F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan. F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $30.67 on December 31, 2020. F1 · derivative.exercise_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F1 · derivative.expiration_date: Mr. Kurzius elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock. F4 · balance_after: Represents an aggregate amount of Deferred Stock Units owned by the reporting person as of fiscal year end, which includes Deferred Stock Units which were inadvertently excluded from prior filings, awarded during the years of 2019 and 2020. The number of Deferred Stock Units issued on each such award date is the amount of cash deferred divided by the closing price of a share of Elanco common stock on the award date. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 20:33 UTC | MCCORMICK & CO INC MKC · Entity 1416 | GrantOptions - Right to Buy · Derivative | 532,198 | $0.00 Strike: $93.49 | $0.00 |
DisclosureSEC source: 0000063754-20-000201 · edgar.xml · derivative · entry 7 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 532,198 Underlying: Common Stock- Voting · 532,198 shares Expires not disclosed F3 · derivative.exercise_date: The option grant vests after the third anniversary date and is only exercisable if certain stock price performance requirements are met. The performance requirements are an increase in the common stock non-voting price of 60% for 1/3 of the options, an increase in the common stock non-voting price of 80% for 1/3 of the options, and an increase in the common stock non-voting price of 100% for 1/3 of the options, in each case within five years of the grant date. Both the vesting date and perfomance requirements must be met for the portion of the grant to become exercisable. F3 · derivative.expiration_date: The option grant vests after the third anniversary date and is only exercisable if certain stock price performance requirements are met. The performance requirements are an increase in the common stock non-voting price of 60% for 1/3 of the options, an increase in the common stock non-voting price of 80% for 1/3 of the options, and an increase in the common stock non-voting price of 100% for 1/3 of the options, in each case within five years of the grant date. Both the vesting date and perfomance requirements must be met for the portion of the grant to become exercisable. F1 · balance_after: Amounts reported herein reflect the Issuer's 2 for 1 stock split of its common stock and common stock non-voting, effective November 30, 2020. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:23 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 5,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-20-000511 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,960 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 20:45 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionRestricted Stock Units · Derivative | 14,020 | $0.00 | $0.00 |
DisclosureSEC source: 0000063754-20-000187 · edgar.xml · derivative · entry 8 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,021 Underlying: Common Stock- Voting · 14,020 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; No purchase price required. F4 · price: The Rrestricted Stock Units granted on November 27, 2018. F3 · derivative.exercise_date: The Restricted Stock Units vest in thirds over a three year period beginning on November 27, 2019, November 27, 2020 and November 27, 2021. F3 · derivative.expiration_date: The Restricted Stock Units vest in thirds over a three year period beginning on November 27, 2019, November 27, 2020 and November 27, 2021. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 20:45 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Tax withholdingCommon Stock - Voting | 6,772 | $187.05 | $1,266,668.74 |
DisclosureSEC source: 0000063754-20-000187 · edgar.xml · nonDerivative · entry 2 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,698 Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 20:45 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionCommon Stock - Voting | 14,020 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000063754-20-000187 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; No purchase price required. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 20:49 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionOptions - Right to Buy · Derivative | 50,600 | $0.00 Strike: $71.60 | $0.00 |
DisclosureSEC source: 0000063754-20-000138 · edgar.xml · derivative · entry 8 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock- Voting · 50,600 shares Expires 2023-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Option exercised. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 20:49 UTC | MCCORMICK & CO INC MKC · Entity 1416 | SaleCommon Stock - Voting | 50,600 | $200.00 | $10,120,000.00 |
DisclosureSEC source: 0000063754-20-000138 · edgar.xml · nonDerivative · entry 2 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,450 F1 · balance_after: The Reporting Person's direct holdings of teh Issuer's Common Stock-Voting decreased by 14,000 shares as a result of such shares being transferred on April 21, 2020 and evenly split into two seperate grantor retained annuity trusts of which the Reporting Person is a trustee and sole annuiant. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 20:49 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionCommon Stock - Voting | 50,600 | $71.60 | $3,622,960.00 |
DisclosureSEC source: 0000063754-20-000138 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 18:09 UTC | MCCORMICK & CO INC MKC · Entity 1416 | GrantOptions - Right to Buy · Derivative | 60,310 | $0.00 Strike: $138.62 | $0.00 |
DisclosureSEC source: 0000063754-20-000080 · edgar.xml · derivative · entry 6 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,310 Underlying: Common Stock- Voting · 60,310 shares Expires not disclosed F4 · derivative.exercise_date: The option grant becomes exercisable in thirds of each of the first three (3) grant anniversaries. F4 · derivative.expiration_date: The option grant becomes exercisable in thirds of each of the first three (3) grant anniversaries. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 18:09 UTC | MCCORMICK & CO INC MKC · Entity 1416 | GrantRestricted Stock Units · Derivative | 11,951 | $0.00 | $0.00 |
DisclosureSEC source: 0000063754-20-000080 · edgar.xml · derivative · entry 5 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,951 Underlying: Common Stock - Voting · 11,951 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive on share of Common stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in thirds over a three year period beginning March 15, 2021, March 15, 2022 and March 15, 2023. F3 · derivative.expiration_date: The Restricted Stock Units vest in thirds over a three year period beginning March 15, 2021, March 15, 2022 and March 15, 2023. Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 20:17 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionRestricted Stock Units · Derivative | 3,497 | $0.00 | $0.00 |
DisclosureSEC source: 0000063754-20-000054 · edgar.xml · derivative · entry 11 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,994 Underlying: Common Stock - Voting · 3,497 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units; no purchase price required. F10 · price: Restricted Stock Units granted on March 27, 2019. F9 · derivative.exercise_date: The Restricted Stock Units vest in thirds over a three year period beginning on March 15, 2020, March 15, 2021 and March 15, 2022 F9 · derivative.expiration_date: The Restricted Stock Units vest in thirds over a three year period beginning on March 15, 2020, March 15, 2021 and March 15, 2022 Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 20:17 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionRestricted Stock Units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000063754-20-000054 · edgar.xml · derivative · entry 10 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,251 Underlying: Common Stock - Voting · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units; no purchase price required. F8 · price: Restricted Stock Units granted on March 28, 2018. F7 · derivative.exercise_date: The Restricted Stock Units vest in thirds over a three year period beginning on March 15, 2019, March 15, 2020 and March 15, 2121. F7 · derivative.expiration_date: The Restricted Stock Units vest in thirds over a three year period beginning on March 15, 2019, March 15, 2020 and March 15, 2121. Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 20:17 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionRestricted Stock Units · Derivative | 286 | $0.00 | $0.00 |
DisclosureSEC source: 0000063754-20-000054 · edgar.xml · derivative · entry 9 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 286 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Stock Units; no purchase price required. F6 · price: Restricted Stock Units granted on March 29, 2017. F5 · derivative.exercise_date: The Restricted Stock Units vest in thirds over a three year period beginning on March 15, 2018, March 15, 2019 and March 15, 2020. F5 · derivative.expiration_date: The Restricted Stock Units vest in thirds over a three year period beginning on March 15, 2018, March 15, 2019 and March 15, 2020. Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 20:17 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Tax withholdingCommon Stock - Voting | 1,607 | $132.84 | $213,465.85 |
DisclosureSEC source: 0000063754-20-000054 · edgar.xml · nonDerivative · entry 5 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,450 Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 20:17 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionCommon Stock - Voting | 3,497 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000063754-20-000054 · edgar.xml · nonDerivative · entry 4 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Stock Units; no purchase price required. Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 20:17 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Tax withholdingCommon Stock - Voting | 1,953 | $132.84 | $259,426.76 |
DisclosureSEC source: 0000063754-20-000054 · edgar.xml · nonDerivative · entry 3 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,560 Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 20:17 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionCommon Stock - Voting | 4,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000063754-20-000054 · edgar.xml · nonDerivative · entry 2 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Stock Units; no purchase price required. Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 20:17 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionCommon Stock - Voting | 286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000063754-20-000054 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Subject to deferred receipt. F2 · price: Restricted Stock Units; no purchase price required. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:23 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Tax withholdingCommon Stock - Voting | 6,895 | $162.91 | $1,123,264.45 |
DisclosureSEC source: 0000063754-20-000029 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,977 F1 · shares: Shares withheld for taxes on the shares previously reported on 1/22/2020 for McCormick's Long-Term Incentive Program. Read SEC document |
| January 20, 2020 Filed Jan 22, 2020 19:12 UTC | MCCORMICK & CO INC MKC · Entity 1416 | GrantCommon Stock - Voting | 14,384 | $0.00 | $0.00 |
DisclosureSEC source: 0000063754-20-000011 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,872 F1 · shares: Shares awarded pursuant to McCormick's Long-Term Incentive Program (LTIP) for the three (3) year performance cycle beginning on December 1, 2016 and ending on November 30, 2019. Read SEC document |
| January 13, 2020 Filed Jan 22, 2020 19:12 UTC | MCCORMICK & CO INC MKC · Entity 1416 | OtherPhantom Stock · Derivative | 53.9188 | $165.30 | $8,912.78 |
DisclosureSEC source: 0000063754-20-000011 · edgar.xml · derivative · entry 4 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Non-Qualified Retirement Savings Plan Disclosed balance after: 14,429.3715 Underlying: Common Stock - Voting · 53.9188 shares Expires not disclosed F3 · derivative.exercise_price: Dividend Reinvestment F3 · derivative.exercise_date: Dividend Reinvestment F3 · derivative.expiration_date: Dividend Reinvestment Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 00:47 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 6,496 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000577 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,075 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:04 UTC | MCCORMICK & CO INC MKC · Entity 1416 | Exercise / conversionRestricted Stock Units · Derivative | 14,020 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000063754-19-000203 · edgar.xml · derivative · entry 6 Kurzius Lawrence Erik · CIK 0001352090 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,041 Underlying: Common Stock - Voting · 14,020 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; no purchase price required. F4 · price: Restricted Stock Units granted on November 27, 2018. F2 · derivative.exercise_date: The Restricted Stock Units vest in thirds over a three year period beginning on November 27, 2019, November 27, 2020 and November 27, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in thirds over a three year period beginning on November 27, 2019, November 27, 2020 and November 27, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.